- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Jindalee Lithium
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NeoGenomics Shares Financial Report for Q2
NeoGenomics announced their financial results for the second quarter of 2017.
NeoGenomics (NASDAQ:NEO) announced their financial results for the second quarter of 2017.
As quoted in the press release:
Second Quarter 2017 Highlights:
- 16% increase in clinical genetic testing volume(1)
- 5% increase in consolidated revenue to $66.1 million
- 13% reduction in average cost per clinical genetic test(1)
- Significant improvement in Gross Margin to 47.2% from 45.3% in Q2 16
- GAAP EPS of ($0.03) per share and non-GAAP Adj. Diluted EPS(2) of $0.04 per share
Consolidated revenues for the second quarter were $66.1 million, an increase of 5% over the same period last year. Clinical genetic test volume(1) increased 16% year over year, and average revenue per clinical genetic test (“Revenue per Test”) decreased by 8% to $355, primarily due to changes in test mix as a result of our leadership in the rapidly growing field of immuno-oncology testing, which currently has lower average pricing because of the large influx of PD-L1 testing.
Consolidated gross profit improved by $2.6 million compared to last year’s second quarter and consolidated gross margin improved by 190 basis points to 47.2%. Gross margin improvement was driven by increased clinical test volume and realization of certain Clarient synergies. Average cost-of-goods-sold per clinical genetic test (“Cost per Test”) declined by 13% compared to the second quarter of 2016.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.